



NEMEX

RESOURCES LIMITED

ACN 146 243 843



12 August 2014

Fast Facts

Capital Structure

Shares on issue	157.4M
Options	86.9M
Performance Rights	9.0M
ASX Code	NXR

Directors &

Senior Management

Patrick Flint

Chairman

Peter Turner

Technical Director

Paul Jurman

Non-Exec Director &

Company Secretary

Project Highlights

WBT Investment

- *Biometric technology*
- *Potential global market*
- *Strong management*

Guinea (Iron)

- *High-grade iron discovery*
- *Large resource potential*
- *Targeting DSO production*

Côte d'Ivoire (Gold)

- *Geophysical anomalies*
- *Exciting opportunity*
- *Under-explored country*

Contacts

Mr Patrick Flint

T: +61 8 9388 2277

www.nemexres.com.au

Security Biometric Technology Successfully Adapted to Hand Held Platform

Highlights

- Wavefront Biometric Technologies Pty Ltd (WBT) has **successfully completed Phase 1** of its technology development program, on time and on budget.
- WBT has adapted its patented biometric technology for reliable and secure authentication of a person's identity **to a hand held platform**.
- Phase 2 of the development program will focus on improving the design and performance of the prototype unit, and initiating performance reviews using test groups.
- WBT's objective is to demonstrate the enhanced product to potential users in early 2015, and commence the commercialisation process.

Nemex Resources Limited (NXR) is pleased to advise that WBT has completed Phase 1 of its technology development program. The key achievement of this Phase 1 work has been to adapt WBT's patented biometric technology to a hand held platform.

Successful completion of the Phase 1 program is a major achievement for WBT as:

- It confirms the potential for WBT's unique biometric technology to offer a security solution in the mobile banking sector.
- It establishes the foundations for WBT to commence discussions with potential users of the technology (such as device manufacturers).
- It demonstrates the strength of WBT's development team led by Dr Ed Sarver. Dr Sarver has set an aggressive development schedule, and achieved the Phase 1 objectives on time and on budget.



WBT has developed and patented a biometric technology for reliable and secure authentication of a person's identity. The technology authenticates a person's identity based on the pattern of light reflected back from the tear film on the corneal surface of the eye. WBT initially developed a desktop device to deliver its identity authentication solution.

In April 2014 NXR entered into an agreement with WBT pursuant to which NXR agreed to fund further development of WBT's technology on a staged basis. WBT's main objective is to commercialise the technology (initially) in the mobile banking sector. The technology has potential applications across global sectors including banking, healthcare, military, aviation and border control.

Phase 1 of the development program was to adapt the WBT technology onto a hand-held platform and, more specifically, be able to demonstrate that the hand-held platform will:

- Acquire a live image for authentication
- Automatically process the image for features used for authentication
- Enroll an individual
- Demonstrate authentication of the enrolled individual

WBT has now advised that phase 1 of the development program has been successfully completed via an attachment to a hand-held device. The Phase 1 development program was completed on time and on budget.

NXR now has a period of 20 business days to conduct its own investigations and decide on whether to exercise its option and invest a further \$625,000 to fund Phase 2 of WBT's product development, and thereby acquire an additional 10% in WBT, bringing its interest in WBT to 30%. NXR has the capacity to fund this further investment from its existing cash reserves.

The planned Phase 2 development program, which is budgeted to take 4 to 6 months to complete, will focus on improving product design, software performance, producing four prototype units for parallel testing, and initiating a staged evaluation of system performance involving an internal study using a group of test subjects. WBT's objective is to demonstrate the enhanced product to potential users in early 2015, and commence the commercialisation process.

Detailed information about Nemex is available at www.nemexres.com.au

For further information about Nemex and its investment in WBT contact:

Patrick Flint

Chairman

P: 08 9388 2277

E: pflint@nemexres.com.au